Indexing hint: Randomized controlled trial · 2022
Tirzepatide Once Weekly for the Treatment of Obesity.
Jastreboff et al. 2022The New England journal of medicinecited by 2,802
PMID 35658024DOI 10.1056/nejmoa2206038PUB-35658024
Trial · Observational
RecruitingPhase not statedRegistry dataShort name Diagenix
Greece
1 trial · 1 ongoing
Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.
Obesity is a chronic multifactorial disease with a strong genetic component. Although glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists, such as tirzepatide, are highly effective treatments for obesity, substantial inter-individual variability in weight loss response remains. Genetic factors may contribute to these differences in treatment outcomes. The aim of this prospective cohort study is to investigate whether a Genetic Risk Score (GRS) and selected obesity-related single nucleotide polymorphisms (SNPs) can predict weight loss response to semaglutide or tirzepatide in adults with obesity. Participants initiating treatment with either medication will undergo clinical, biochemical, and genetic assessment at baseline and will be followed for six months. The study will evaluate the association between genetic markers and treatment response and develop predictive models integrating genetic and clinical variables. The findings may contribute to the development of personalized treatment strategies for obesity.
Other
Semaglutide or Tirzepatide
Adults with obesity initiating treatment with semaglutide or tirzepatide as part of routine clinical care. Participants are followed prospectively for 6 months to evaluate weight loss response and its association with genetic risk score.
Outcomes the sponsor listed as primary.
Percentage weight loss at 6 months
Time frame · 6 months
Percentage change in body weight from baseline to 6 months following treatment with semaglutide or tirzepatide. The association between weight loss response and genetic risk score (GRS) as well as obesity-related single nucleotide polymorphisms (SNPs) will be evaluated.
Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.
No results are posted for this trial.
A trial that is still running, or that stopped early, may post results later.
Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works
Studies that cite this trial.
2 studies on this page
Indexing hint: Randomized controlled trial · 2022
Jastreboff et al. 2022The New England journal of medicinecited by 2,802
PMID 35658024DOI 10.1056/nejmoa2206038PUB-35658024
Indexing hint: Randomized controlled trial · 2021
Wilding et al. 2021The New England journal of medicinecited by 3,862
PMID 33567185DOI 10.1056/nejmoa2032183PUB-33567185
References listed at the registry that are not in PepBank. They link to PubMed.
Who could join, as posted.
PepBank is a research reference. Talk to a doctor before you use any peptide.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated